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Stllnllllary 
Transgenic mice expressing human major histocompatibility complex (MHC) class II molecules 
would provide a valuable model system for studying human immunology. However, attempts 
to obtain human class II-restricted T cell responses in such transgenic mice have had only limited 
success, possibly due to an inability of mouse CD4 to interact efficiently with human MHC 
class II molecules. To circumvent this problem, we constructed recombinant MHC class II genes 
in which the peptide-binding domain was derived from human DR sequences whereas the CD4- 
binding domain was derived from mouse I-E sequences.  Purified chimeric human/mouse MHC 
class II molecules were capable of specifically binding DR-restricted peptides.  Human B cell 
transformants that expressed these chimeric MHC class II molecules could present peptide antigens 
to human T  cell clones.  Expression of these chimeric class II molecules in transgenic mice led 
to the intrathymic deletion of T cells expressing superantigen-reactive  V/3 gene segments, indicating 
that the chimeric class II molecules could influence the selection of the mouse T cell repertoire. 
These transgenic mice were fully capable of mounting human DR-restricted immune responses 
after challenge with peptide or whole protein antigens. Thus,  the chimeric class II molecules 
can serve as functional antigen presentation molecules in vivo. In addition, transgenic mice expressing 
chimeric class II molecules could be used to generate antigen-specific mouse T cell hyhridomas 
that were capable of interacting with human antigen-presenting cells. 
M 
HC class II proteins are cell surface heterodimers com- 
posed of a nearly invariant o~ chain and a highly poly- 
morphic/5 chain. The primary function of these molecules 
is to present peptide fragments derived from processed an- 
tigens to CD4-bearing T  cells. Interactions between MHC 
class II-peptide complexes and TCRs play a central role in 
the selection of the T  cell repertoire and in the elicitation 
of an immune response. The inheritance of particular MHC 
class II alleles is genetically associated with susceptibility to 
certain autoimmune diseases such as type I diabetes and rheu- 
matoid arthritis (1, 2). The basis of the association between 
MHC class II genes and autoimmune disease is not known, 
but could be due to several immunological mechanisms. Poly- 
morphic amino acid residues in the class II peptide-binding 
groove might differentially bind potential autoantigens. Al- 
ternatively, the expression of particular MHC class II alleles 
might dictate whether autoreactive T cells reach functional 
maturity during development in the thymus. Another ex- 
planation that has been proposed for HLA disease associa- 
tions is molecular mimicry between environmental pathogens 
and MHC class II proteins (3, 4). Sequence homologies be- 
tween CMV proteins (5), EBV proteins (6, 7),  and disease- 
associated  MHC class II molecules have been described, al- 
though the mechanisms by which these homologies could 
lead to autoimmune disease  are not clear. 
A model system in which human MHC class II molecules 
were expressed in transgenic mice would be of great benefit 
for studying the role of these molecules in the induction of 
autoimmune disease. However, previous attempts to generate 
human class II-restricted T cells responses in such transgenic 
mice have had only limited success (8, 9). One possible reason 
for this is an inability of mouse CD4 to interact efficiently 
with human MHC class II molecules (10-13). This xenogeneic 
barrier would be expected to result in inefficient interactions 
between mouse CD4-positive T cells and human class II-ex- 
pressing APCs in the transgenic mice. It seemed reasonable 
that this barrier could be overcome by employing chimeric 
human/mouse MHC class II molecules in which the CD4- 
binding domain of the human protein is replaced by the cor- 
responding domain of the mouse protein. Experiments using 
human class II molecules which had been altered by exon 
shuffling (12,  13) or point mutation (14) have identified a 
region on the/32 domain of human class II molecules that 
is involved in binding to CD4. Direct binding studies using 
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class II B2 domain have confirmed these observations (15). 
These studies did not rule out the possibility of additional 
interactions between CD4  and regions  on the MHC  class 
II  ot chain. 
In this report, we describe transgenic mice expressing recom- 
binant MHC class II molecules in which the or1 and/31 do- 
mains of mouse I-E  d were replaced by the corresponding do- 
mains of human DRB1*0401 (DR4Dw4) molecules. These 
molecules should be capable of presenting human class II-re- 
stricted peptides to mouse CD4-positive cells. DR4Dw4 was 
chosen because its expression has been associated with sus- 
ceptibility to autoimmune disease in humans. The inheritance 
of MHC haplotypes containing DR4Dw4 is associated with 
an increased risk of developing rheumatoid arthritis (16-22). 
In addition,  the relative risk of developing type I  diabetes 
is highest in individuals that express DR4Dw4  along with 
DQ*0302 (DQ3.2) or DR1 (1, 23-25). Transgenic mice ex- 
pressing these recombinant molecules should provide a model 
system  for  studying  the  link  between  human  DR4Dw4- 
restricted immune responses  and  autoimmune  disease. 
Materials and Methods 
Mice.  (C57BL/6  x  SJL/J) Fz mice and B10.M/Sn H-2  f mice 
were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Intercrosses and backcrosses  of transgenic founders to B10.M/Sn 
H-2  f were performed in the Merck Research Laboratories animal 
facility under sterile, specific pathogen-free conditions. The experi- 
ments described in this report were performed with H-2  f homozy- 
gous mice from the third or fourth backcross  generations. 
Chimeric MHC Class II Gene Constructions.  For the chimeric 
a  chain, an 8.4-kb HindlII fragment containing the Ea gene was 
subcloned into a modified Bluescript vector in which the EcoRI 
and BamHI sites in the polylinker were destroyed by enzyme diges- 
tion followed by extension with Klenow polymerase. This plasmid 
was digested with EcoRI and BamHI to remove a 1.1-kb fragment 
containing the second exon of the Eot gene. A 696-bp PCR product 
was obtained by amplification of Priess DNA with primers flanking 
the second exon of the DR a  chain gene (5'-GGG-GGA-TCC-TGG- 
CCT-AAG-TGT-AT'IZFAA-TGC-CCG-G-3'  and 5'-GGG-GAA-TTC- 
CTA-TGG-ATT-CCC-GTG-TCC-AGG-AGT-3') and  then cloned 
into this plasmid.  An 8.0-kb HindlII fragment was isolated from 
the final plasmid subclone for microinjection into fertilized eggs. 
For the chimeric/~ chain, a 2.2-kb BamHI/HindlII fragment con- 
taining  the first  exon of the E3  d gene  was  subcloned into the 
pACYC184  vector and then altered by site-directed mutagenesis 
so that three nucleotides of the exon were changed to the corre- 
sponding nucleotides of the first exon of DR4Dw4. This was ac- 
complished by PCR  amplification using  a primer flanking the 
BamHI  site  of the  insert  (5'-GAT-ATA-GGC-GCC-AGC-AAC- 
CGC-ACC-T-Y) and a primer that spanned an ApaLI site in the 
first intron (5'-TGA-GGT-GTG-CAC-TTA-CGT-CGG-GTG-TCC- 
CCG-ACC-AAA-GC-Y). The PCR product was ligated back into 
a BamHI/ApaLI partial digest of the plasmid subclone.  A 1.9-kb 
EcoRI/BamHI fragment containing the altered first exon was then 
used to replace the corresponding fragment of plasmid clone that 
contained a 6.6-kb ClaI/EcoRI insert encompassing the 5' end of 
the  E3  a gene.  Next,  a  1.1-kb  BamHI/HindlII  fragment  con- 
taining the DR4Dw4 ~ chain second exon was isolated from the 
X713 phage clone (26). The ends of this fragment were converted 
to EcoRI and BamHI and ligated to the 6.6-kb ClaI/EcoRI frag- 
ment described above, along with a 5.9-kb Bluescript subclone that 
had an insert containing exons 3-6 of the E3  d gene. A  10.6-kb 
KpnI/NotI fragment was isolated from the final plasmid subclone 
for microinjection into fertilized eggs. 
Cell Lines.  All cell lines were maintained in RPMI medium 
supplemented with 10% FCS. The B cell line, MUD45, was gener- 
ated by the fusion of LPS-activated B10.PL spleen cells to the A20 
B-lymphoma line (27). As a result of chromosomal segregation, 
MUD45 cells express the H-2  u MHC haplotype from B10.PL, but 
not the H-2  a MHC haplotype from the A20 cells. Chimeric MHC 
class II genes  and  the pSV2neo vector were cotransfected into 
MUD45  cells by electroporation using a gene pulser (Bio-Rad 
Laboratories,  Richmond, CA). Stable transformants were selected 
by culturing at limiting dilution with 1 mg/ml G418. The 17-11 
human T cell clone was obtained from the ImmuLogic Pharmaceu- 
tical Corporation (Palo Alto, CA), and is specific for HA(307-319) 
presented in the context of DR4Dw4. 
Flow Cytometry.  The mAbs used for detecting class II molecules 
were as  follows (specificity  is  indicated  in  parentheses):  LB3.1 
(DRotl),  L243  (DRotl),  L227  (DRB1),  MTM39.6  (DRB1), 
MTM23.4 (DRotl), MTM16.7 (DRot1/31), MTM12.1 (DRot1/31), 
MTM45.6 (DRY1),  and Y3P (I-A). LB3.1 and Y3P were purified 
from cell culture supernatants. L243 was purchased from Becton 
Dickinson & Co. (San Jose, CA). The MTM series of Abs were 
gifts from the ImmuLogic Pharmaceutical Corporation. The class 
II domain specificity of these antibodies was determined by com- 
parison of single  and double chain transformants expressing  the 
chimeric MHC class II gene products. The mAbs used for detecting 
T cell populations were as follows: F23.2 (V~8.2), RR3-15 (V~11), 
RR4-7 (V36), MR5-2 (V38.1/V38.2), B20.6 (Va2), and 500AA2 
(CD3). These Abs were either purified from cell culture superna- 
tants or purchased from PharMingen (San Diego, CA).  Protein 
A-purified antibodies were labeled using NHS-biotin (Pierce, Rock- 
ford, IL) according to the manufacturer's directions. The fluoroscein- 
conjugated mAbs used  to identify H-2  r homozygous mice were 
KH95 (Db), KH43 (Ds), 15-5-5 (Dr),  7-16.17 (A  b, As), and Y3P 
(Af).  KH95,  KH43,  15-5-5,  and  7-16.17 were purchased  from 
PharMingen.  PBLs  from  H-2  f homozygous mice were stained 
with  15-5-5 and Y3P, but not with KH95, KH43, and 7-16.17. 
For single colored stains, 5  x  10  s cells were incubated with FITC- 
conjugated Abs or sequentially incubated with biotin-conjugated 
Abs followed by FITC-conjugated streptavidin (Fisher  Scientific 
Co., Pittsburgh, PA). For two-colored stains, cells were sequen- 
tially  incubated  with  FITC-conjugated  first-step  Ab,  biotin- 
conjugated second-step Ab, and PE-conjugated streptavidin (Fisher 
Scientific Co.). Lymphocytes were purified from peripheral blood, 
spleen,  or lymph nodes by density gradient centrifugation using 
Lympholyte M (Cedarlane Laboratories,  Westbury, NY). Stained 
cells were analyzed using a FACScan  |  (Becton Dickinson & Co.). 
MHC Class II/Peptide Binding Assays.  Purified native DR4Dw4 
molecules (2.5 riM) or purified chimeric MHC class II molecules 
(1.25 nM) were incubated for 18 h at 37~  with peptides that were 
labeled  at the NH2 terminus with biotin. Bound peptides  were 
separated  from free peptides by immobilizing the MHC class II 
molecules  on microtiter plates  incubated overnight at 4~  with 
10/~g/ml of affinity purified L227 mAb. Bound biotinylated pep- 
tides  were detected by sequential incubations with streptavidin- 
europium  followed by  a  chelating-enhancement  solution,  and 
fluorescence was quantified using a plate fluorometer (Delfia model 
1234; Pharmacia LKB Biotechnology, Uppsala,  Sweden). 
T Cell Proliferation Assays.  Mice were immunized in the hind 
footpads with 50 nmol of antigen emulsified  in CFA. Lympho- 
174  Human MHC Class II-restricted T Cell Response in Transgenic Mice cytes were isolated from popliteal, inguinal, and paraaortic lymph 
nodes 10 d after immunization. 4  x  103 cells were then cultured 
in microtiter plates for 4 d in RPMI/10% FCS with serial dilu- 
tions of antigen. For human T cell clones, 3  x  104 T cells and 
10  s glutaraldehyde-fixed  APCs were incubated for 2 d with serial 
dilutions of antigen.  1 #Ci of [3H]thymidine was added to the 
wells during the last 16 h of culture. Plates were then harvested 
and counts  per minute  was  determined by liquid  scintillation 
counting. 
T Cell Hybridomas.  Lymph node cells from immunized mice 
were cultured for 3 d in the presence of 100/zM of antigen. Live 
cells were purified over lympholyte M gradients and fused to a 
BW5147 variant cell line (28). Hybridomas were selected in cul- 
ture medium supplemented with HAT. The specificity  of the hy- 
bridomas were assessed in IL-2  release assays. Single  cell clones were 
obtained by culture a limiting dilution. 
1L-2 Release Assays.  Hybridoma cells and APCs were cocul- 
tured overnight with serial dilutions of antigen in flat-bottom mi- 
crotiter plates. Supernatants were then transferred to culture wells 
containing 5 x  103 HT-2 indicator cells. The HT-2 cells were then 
incubated for 24 h with 1 #Ci of [3H]thymidine  added during the 
last 5 h of culture. Plates were harvested and counts per minute 
was determined by liquid scintillation counting. 
Results 
Generation of Chimeric Human~Mouse MHC Class II Mole- 
cules.  Mouse MHC class II Ecx and E/3 chain genes (E  a) 
were genetically engineered to encode proteins in which the 
oel (amino acids 1-85) and the/31 domains (amino acids 1-96) 
were replaced by the corresponding amino acids of the human 
MHC class II protein, DR4Dw4 (Fig.  1). In the resulting 
chimeric MHC class II molecules, the peptide-binding do- 
main is derived from human DR4Dw4 sequences, whereas 
the putative CD4-binding domain is derived from mouse E  a 
sequences.  The promoter regions that lie upstream of the 
recombinant MHC class II genes were derived from mouse 
sequences to ensure proper tissue-specific expression in mouse 
cells (29,  30). 
The cx and/3 gene constructions were cotransfected into 
the B-lymphoma linee, MUD45 (see Materials and Methods). 
Stable transformants were analyzed by flow cytometry with 
a panel of eight mAbs specific for DR oll and/or/31 domains. 
All mAbs that were tested bound to the cell surface of the 
transformants, suggesting that the chimeric MHC class II 
molecules were folded into a proper conformation (data not 
shown). Analysis of cells singly transfected with either the 
ot or the/3 chain gene construction indicated that heterodi- 
mers could form between Ecx and the chimeric fl chain and 
between E3  and the chimeric c~ chain. 
Characterization of Chimeric MHC Class II Molecules.  The 
ability of chimeric MHC class II molecules to bind DP,- 
restricted peptides was evaluated. Cell lysates from the stable 
B cell transformants were passed over an affinity column con- 
taining the mAb LB3.1, which binds to the cxl domain of 
DR heterodimers. Chimeric cx//3 heterodimers as well as chi- 
meric cx/E3 heterodimers are copurified using this affinity 
column. The purified molecules were incubated with labeled 
peptides and then immobilized on microtiter plates coated 
with the DR/31-specific mAb, L227. This assay measures 
the ability of peptides to bind only to chimeric cx/3 hetero- 
dimers since the copurified chimeric ol/E/3 heterodimers are 
not recognized by L227. A synthetic peptide derived from 
influenza virus hemagglutinin, HA(307-319),  was capable of 
binding to chimeric MHC class II molecules (Fig. 2). Binding 
was not observed  for OVA (323-339),  a peptide that does 
not bind to DR4Dw4.  Specific binding was also observed 
with three other DR-restricted synthetic peptides:  myelin 
basic protein (90-102), heat shock protein (2-14), and influenza 
nucleoprotein (383-395).  The chimeric MHC class II mole- 
cules bound peptides with similar affinities to those of native 
DR4Dw4 molecules purified from the human B cell line, 
Priess. 
The chimeric ot and/3 gene constructions were also cotrans- 
fected into the human B cell line, IBW4, which does not 
express DR4Dw4. The resulting stable transformants acquired 
the ability to present antigen to DR4Dw4-restrictd human 
T cell clones (Fig. 3). Thus, the chimeric MHC class II mol- 
ecules are capable of binding DR4Dw4-restricted peptides 
and of interacting with DR4Dw4-restricted TCRs. 
Generation of Transgenic Mice that Express Chimeric MHC 
Class II Molecules.  The chimeric cx and/3 chain genes were 
coinjected into fertilized eggs derived from (C57BL/6  x 
SJL/J)F2  mice.  Nine  transgenic  founders  that  had  both 
transgenes integrated into the germline, two founders that 
contained only the/3 chain transgene, and one founder that 
contained only the cx chain transgene were obtained. The 
founders were intercrossed with mice from the B10.M strain 
which expresses an H-2  f MHC haplotype. H-2  f homozygous 
mice do not have endogenous Eol or E/3 chains because  of 
mutations in the relevant  MHC class II genes (31, 32).  F1 
transgenic  mice  were  then  backcrossed  to  B10.M.  H-2  f 
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Figure  1.  Schematic  diagram of chimeric 
human/mouse MHC class II genes. Mouse- 
derived sequences are represented  by open rec- 
tangles, human-derived  sequences  by stippled 
rectangles, and plasmid-derived  sequences by 
striped rectangles.  Exons  are represented  by  long 
rectangles and are numbered. 
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Figure  2.  Chimeric MHC class 
II molecules can bind DK4Dw4-re- 
stricted peptides.  Binding assays were 
performed  with  native DR.4Dw4 
molecules purified from Priess cells 
and with  chimeric MHC  class II 
molecules  purified  from  mouse 
B-lymphoma transformants. A pep- 
tide that binds to DR4Dw4  (HA 
[307-3191) and a peptide that does 
not bind to DR4Dw4 (OVA [323- 
3391"  ) were used as ligands in the 
binding assays.  Maximum  signals 
were 173,476 fluorescent units for 
the DR4Dw4 molecules and 53,503 
fluorescent units for the chimeric 
MHC  class II molecules. 
homozygous transgenic offspring from these crosses  were 
identified and used in further backcrosses to B10.M. By placing 
the transgenes onto an H-2 f homozygous background, the 
possibility of heterodimer formation between the chimeric 
MHC class II ot and 3  chains and endogenous mouse Ec~ 
and Eft chains was eliminated. A transgenic line, DR4-31, 
was established from the founder whose progeny had the 
highest transgene expression levels. In this line,  cell surface 
chimeric MHC class II molecules are present at about one- 
half the level  normally observed with  endogenous mouse 
Ec~/E3  molecules.  Lymphocytes isolated  from  peripheral 
blood, spleen, and lymph nodes of transgenic mice were ana- 
lyzed by two-color flow cytometry using Abs that bind to 
mouse A f (Y3P) and human DR4Dw4 (L243) (Fig. 4). The 
chimeric MHC class II molecules were specifically coexpressed 
on virtually all  Af-positive lymphocytes (i.e.,  B  cells  and 
macrophages). In addition, cell surface levels of the chimeric 
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Figure  3.  Chimeric MHC class II molecules can present antigen to a 
DR4Dw4-restricted  human  T  cell clone.  Proliferative responses  of an 
HA(307-319)-specific, DR4Dw4-restricted human T cell clone, 17-11, are 
shown after culture with or without various glutaraldehyde-fixed APCs. 
The expressed MHC class II haplotype of each APC line is shown. The 
APCs used were Priess (DR4Dw4 positive), IBW4 (DR4Dw4 negative, 
DR1 positive), and IBW4 transformed with chimeric MHC class II genes 
(DR4Dw4  negative,  DR1  positive,  chimeric class II positive). 
MHC class II molecules were increased by three- to fourfold 
after overnight incubation of splenic B cells with recombinant 
IL-4, indicating that the expression of the transgenes can be 
physiologically regulated (data not shown). The transgenic 
mice appeared healthy and did not show any symptoms of 
spontaneous autoimmune disease. 
Chimeric MHC Class II Molecules Influence the Mouse T Cell 
Repertoire in Transgenic  Mice  The ability of the chimeric MHC 
class II molecules to present endogenous superantigens to T 
cells in the transgenic mice was evaluated.  One consequence 
of the presentation of endogenous superantigens is the clonal 
deletion of T cells expressing particular TCR fl chain vari- 
able regions such as Vflll  (33,  34).  This deletion is most 
evident in mouse strains that express I-E molecules, such as 
DBA/2 mice that express I-E  d. The percentage of splenic T 
cells expressing receptors bearing V311 was significantly re- 
duced in transgenic mice (0.5 compared with 4.8% in non- 
transgenic controls) (Fig.  5).  The transgenic mice did not 
have reductions in the percentage of T cells bearing receptors 
containing Vfl6, Vfl8.1, Vf18.2, Vf18.3, or Vot2. These data 
suggest that chimeric MHC class II molecules can present 
endogenous superantigens to mouse T cells. Clonal deletion 
of mature Villi-bright thymocytes was also observed in trans- 
genic mice (data not shown). This indicates that chimeric 
MHC class II molecules are expressed intrathymically where 
they  could  influence  the  selection  of the  mouse  T  cell 
repertoire. 
Chimeric MHC Class II Molecules Can Act As a Restricting 
Element in Transgenic Mice.  The ability of the transgenic mice 
to mount human MHC class II-restricted immune responses 
was evaluated using the DR-binding peptide HA(307-319) 
as a model antigen. Transgenic mice and nontransgenic lit- 
termates were primed with HA(307-319) emulsified in CFA. 
Draining lymph nodes cells were isolated 10 d later and re- 
stimulated with the peptide in vitro. HA(307-319)-specific 
proliferative responses were observed only in the transgenic 
mice (Fig.  6 a). These proliferative responses could be in- 
hibited with the LB3.1 mAb, but not the Y3P mAb, demon- 
strating that the responses were restricted to chimeric MHC 
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Figure 4.  Tissue-specific  expression of 
chimeric  MHC class II molecules  in trans- 
genic mice. Expression of chimeric MHC 
class II molecules was evaluated  by two- 
color flow  cytometry  using mAbs specific 
for  mouse A  f  (Y3P) and  human DR. 
(I.243). Contour  double  log plots  of  fluores- 
cent intensity  are shown  for 10,000 spleno- 
cytes from a transgenic mouse and a non- 
transgenic littermate.  Similar  results were 
obtained  on lymphocytes  isolated  from  pe- 
ripheral blood and from lymph nodes. 
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Figure  5.  Deletion  of  V~ll- 
positive T cells in chimeric MHC 
class II transgenic mice. The pres- 
ence of VB11-positive T cells was 
evaluated  by two-color  flow  cytom- 
etry using mAbs specific  for CD3 
(500AA2) and human  V/311 (RR3- 
15). Contour double log plots of 
fluorescent intensity  are shown for 
30,000 splenocytes  from  a transgenic 
mouse and a nontransgenic  litter- 
mate. The  percentage of V/~11- 
positive splenic  T cells  is indicated. 
class II molecules. In addition, the response to purified pro- 
tein derivative (PPD) in the transgenic mice was partially in- 
hibited by LB3.1 (Fig. 6 B). This indicates that the chimeric 
MHC class II molecules can serve as restricting elements in 
the immune response to mycobacterial protein antigens. 
Generation of DR 4Dw4-restricted, Antigen-specific Mouse T 
CellHybridomas.  It has not been possible to generate stable 
human T  cell hybridomas due, at least in part, to the lack 
of an appropriate fusion partner. The transgenic mice described 
in this report offer an alternative means of raising human 
class II-restricted T cell hybridomas. T cells from HA(307- 
319)-immunized mice were fused to a TCR-negative variant 
of the BW5147 thymoma line (28). T cell hybridomas were 
obtained that could respond to HA(307-319)  presented by 
transgenic, but not by nontransgenic, spleen cells (Fig. 7 A). 
The DR4Dw4 restriction specificity of these hybridomas was 
confirmed by demonstrating their ability to respond to an- 
tigen presented by stable transformants of the Chinese ham- 
ster ovary (CHO)  cell line that expressed  DR4Dw4.  The 
hybridomas could also respond to antigen presented by the 
DR4Dw4-positive EBV transformed B cell line, Priess,  or 
by PBLs isolated from a DR4Dw4-positive individual. 
These transgenic mice can be  used to raise  DR4Dw4- 
restricted T  cells specific for any immunogenic antigen, in- 
cluding human proteins. For instance, DR4Dw4-restricted 
mouse T cell hybridomas specific for human serum albumin 
have been generated from these mice (Fig.  7 B). These hy- 
bridomas could respond to freshly isolated human PBLs from 
a DR4Dw4-positive individual without the addition of ex- 
ogenous antigen. 
Discussion 
Recombinant gene constructions in which sequences en- 
coding the human DR4Dw4 peptide-binding domain were 
spliced onto the mouse E a gene were used to create  trans- 
genic mice that were capable of generating human MHC class 
II-restricted T cell responses. The DR4Dw4-derived peptide- 
binding domain of the chimeric class II molecules appeared 
to be folded into a proper conformation since these mole- 
cules: (a) were recognized by a panel of DR-specific mAbs; 
(b) could bind DR-restricted peptides with similar affinities 
to those of native DR4Dw4; and (c) could present antigen 
to a DR4Dw4-restricted human T cell done. Thus, the od/B1 
peptide-binding domain may fold somewhat independently 
of the rest of the class II molecule. 
The chimeric class II molecules are  fully functional as 
antigen-presenting  molecules in the transgenic mice as demon- 
strated by the generation of DR4Dw4-restricted T  cell re- 
sponses after immunization with peptide or whole protein 
antigens. This demonstrates that the repertoire of mouse TCRs 
is sufficiently diverse to allow for the selection of  human MHC 
177  Woods  et al. Figure 6.  Lymph  node proliferative  responses 
in chimeric  MHC dass II transgenic  mice.  Antigen- 
recall responses to (A) HA(307-319) and (B) PPD 
are shown for a transgenic mouse  and a nontrans- 
genic  littermat~ MHC class II blocking  Abs specific 
for A  t (Y3P) and DR (LB3.1) were added where 
indicated. Blocking  Abs were added at 10/zg/ml 
on the first day of culture. The mean counts per 
minute plus or minus the standard deviation of 
triplicate  wells are shown for HA(307-319)  at 100 
/zM and PPD at 10/~g/ml. The experiment  was 
repeated on five  transgenic  and five  nontransgenic 
mice with similar results. 
class II-restricted T cells. An analogous approach using chi- 
meric MHC class  I  molecule previously had been used to 
generate transgenic mice in which human MHC class I-re- 
stricted mouse T  cell responses could be obtained (35, 36). 
Human class I-restricted cytotoxic  T cell clones could be raised 
from these animals after challenge with viral antigens. 
Chimeric dass II transgenic animal could be used to generate 
antigen-specific,  DR4w4-restricted mouse T cell hybridomas. 
These are valuable reagents that cannot be generated directly 
from human T cell dones using current technology. Moreover, 
DR4Dw4-restricted T  cells specific  for any immunogenic 
human protein can be obtained from these animals. Conse- 
quently,  these  mice can  be used  to  generate human  self- 
antigen-reactive T cell clones that could not be raised directly 
from humans because of ethical considerations and because 
of tolerance  to  self-antigens.  As  an  example,  DR4Dw4- 
restricted, human serum albumin-specific T ceils were raised, 
and these cells responded to PBLs from DR4Dw4-positive 
individuals without the necessity of adding exogenous al- 
bumin to the cultures. This demonstrates that human APCs 
can constitutively process serum proteins which can then as- 
sociate with class II molecules. This is consistent with the 
results reported by Panina et al.  (37) in which a human al- 
loreactive clone was shown to be specific for a peptide de- 
rived from human  serum albumin. 
Superantigen-reactive,  Villi-expressing T cells were deleted 
in transgenic mice expressing chimeric class II molecules. This 
result extends the previous observation that DRoe/Efl interspe- 
des heterodimers can cause superantigen-mediated  T cell donal 
deletion in transgenic mice (38). Chimeric ol/Efl or E~/chi- 
meric fl chain heterodimers are not expressed in the trans- 
genic mice since the founders were crossed onto an Eoe/Efl- 
negative H-2  f MHC  haplotype.  The presence of chimeric 
c~/Af3 or Aloe/chimeric fl chain heterodimers in the trans- 
genic mice is unlikely as lymphocytes from H-2  t homozy- 
gous transgenic mice that contained only the chimeric o~ or 
fl chain transgene did not bind to any of the DR-specific 
mAbs tested. Thus, deletion of superantigen-reactive Villi- 
expressing T  cells in the transgenic mice was mediated by 
chimeric c~/chimeric fl chain heterodimers. It is not clear to 
what extent the human and mouse sequences in the chimeric 
class  II  MHC  molecules  contributed  to  this  deletion 
phenomenon. 
The fact that the chimeric class II molecules were func- 
tional in transgenic mice is consistent with the location of 
a CD4-binding site on the c~2 and/or f12 domains of class 
178  Human  MHC Class II-restricted  T Cell Response in Transgenic Mice Figure 7.  Ib2  release responses  of 
DR4Dw4-restricted,  T call  hybridomas.  T 
cell hybridomas  were  raised  by immuniza- 
tion of transgenic mice  followed  by fusion 
of  activated  T cells  with BW5147. Examples 
are shown  of  Ib2 release  after  overnight  in- 
cubation of various APCs with  (.4) an 
HA(307-319)-specific T  cell hybridoma 
(HA33.6) or  (B)  a  human serum al- 
bumin-speeific  hybridoma  (halb17.9). 105 
T cells  were cultured  with either  3 x  10  s 
splenocytes, 3  x  105 PBLs, or 2  x  104 
CHO cells  in microtiter  wells. Ib2 release 
was quantified  by HT-2  bioassay. The mean 
counts per minute of triplicate wells plus 
or minus the standard  deviation  are shown. 
II molecules. However, we have not directly demonstrated 
the interaction of mouse CD4 with these domains. It is pos- 
sible that  the presence of the mouse ot2//~2  domains con- 
tributes to the functionality of the chimeric class II mole- 
cules in transgenic mice for other unknown reasons.  Mouse 
CD4-positive DR4Dw4-restricted T  cell hybridomas were 
capable of responding to antigen presented by human class 
II-positive cells despite the inefficiency of mouse CD4-human 
class II interactions. It is possible that these T  cell responses 
are suboptimal and might be enhanced by the expression of 
human CD4 in the T  cell hybridoma lines. 
The transgenic mice described in  this report are fertile, 
appear healthy, and have not displayed any spontaneous pa- 
thology, despite the association of DR4Dw4 with autoim- 
mune disease in humans. Since susceptibility to autoimmune 
disease is determined by multiple genetic factors, it will be 
of interest to backcross the transgenic mice to other inbred 
strains of mice. The role of DK4Dw4 molecules in autoim- 
mune disease induced by active immunization with poten- 
tial autoantigens such as collagen type II can also be evalu- 
ated using these transgenic mice. 
In summary, we have developed a transgenic mouse model 
in which human DR-restricted immune responses can be ob- 
tained. These mice offer a powerful model system in which 
DR4Dw4-restricted antigenic determinants can be identified 
and in which therapeutic agents that affect DR-restricted im- 
mune responses can be evaluated. These mice should be useful 
for studying the mechanism by which particular DR alleles 
are associated with specific  human  autoimmune diseases. 
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